IKNA

Stats

Summary

ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi

Market Cap: 76.2 Million

Primary Exchange: NASDAQ

Website: ikenaoncology.com

Shares Outstanding: 48.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.419514864297753

Sector: Manufacturing

Industry: Medicinal and Botanical Manufacturing

Ethical Flags

Longest drawdown: 948 trading days

From: 2021-03-29 To: 2024-03-07

Lowest Point: